When a doctor diagnoses a patient with a potentially fatal disease and there’s a medication to cure it, the patient can rejoice while the doctor scribbles a prescription.

One exception is hepatitis C, the virus that infects up to 5 million Americans, including many baby boomers.

With high drug costs and health insurance companies vigilant about health care expenditures, patients with hepatitis C often must forgo medication until the infection progresses, putting them at greater risk of developing liver cancer or cirrhosis of the liver requiring a transplant.

The key reason is Harvoni, a new curative medication manufactured by Gilead Sciences Inc., with a retail cost of $94,500 for a 12-week treatment regimen with the average cost in the $50,000 to $60,000 range. Those prices have led to health insurance policies to approve payment only when patients reach later-stage liver disease.

Advertise with us

It also centers debate on the morality and ethics of this cost-of-cure reality.

“As a clinician, you prefer drugs to be as cheap as possible so there is greater access for the patient,” said Joseph K. Lim, director of the Yale University School of Medicine’s Viral Hepatitis Program. “But the flipside is, if there is no incentive for the manufacturer, there will be limits on the research and development of new therapies, which would have a dramatic impact on curing infections.

“I see both sides, but one thing that’s really challenging is the cost effectiveness of these drugs,” he said. Providing the drug upon diagnosis would be cost-effective, he said, “in terms of preventing long-term complications, cirrhosis, liver failure and the need for transplantation.”

Dr. Lim led a study published Aug. 27 in PLOS One that found that one in four patients with chronic hepatitis C in Connecticut were denied initial approval for the Harvoni drug therapy, with cure rates exceeding 90 percent for the most common strain of the virus. The drug received FDA approval last October.

Records of 129 patients who were prescribed Harvoni (which combines sofosbuvir and ledipasvir into one oral medication) showed that many who initially were denied payment did receive the drug after filing an appeal. Others, however, were forced to wait until their disease reached a certain threshold before payment was authorized.

Advertise with us

Those with advanced liver disease and those covered by Medicare or Medicaid were more likely to receive the drug, the study found. Dr. Lim said the percentage of those rejected for treatment likely is even higher now that health-insurance providers have had time to set stricter payment policies.

“Delay in access may further challenge our ability to cure hepatitis C in this country,” Dr. Lim said.

All drugs in time come off patent, leading to competition with generic drugs. That competitiveness helps stabilize drug costs, “while providing incentives for the development of new treatments and cures,” said Holly Campbell spokeswoman for Pharmaceutical Research and Manufacturers of America.

That factor, she said, explains the “tremendous and sustainable progress against hepatitis C, cancer and other challenging diseases.”

“Developing new treatments and cures is a long, costly and complex process,” she said. “And the science is getting harder as researchers go after the most difficult diseases and develop treatments targeted to individual patients. In fact, only 12 percent of medicines that enter clinical trials eventually make it to the market, and many more fail well before that point.”

Advertise with us

Among other drugs, Praluent, a new heart-disease and anti-cholesterol drug manufactured by Sanofi and Regeneron, is generating debate with its $84,000 retail cost for a 12-week regimen. Juxtapid, another heart drug manufactured by Aegerion Pharmaceuticals Inc., has a retail cost of $30,000 for a one-month supply. Drug companies typically advertise programs to help those with low incomes to obtain the drugs.

High-cost specialty drugs for rare cancers and genetic defects can be better absorbed by health-insurance companies, Dr. Lim said.

Yet in August, a Mayo Clinic commentary signed by 35 cancer physicians supported “a patient-driven initiative and petition to lower the high price of cancer drugs.” It said trends in insurance coverage have put a heavy financial burden on patients with an out-of-pocket share of 20 percent to 30 percent of total costs. That means the patient might have to pay $24,000 to $36,000 a year for a cancer drug costing $120,000.

CVS Caremark said patients requiring specialty drugs represent only 3.6 percent of all patients but account for 25 percent of health-care costs.

FDA spokeswoman Sandy Walsh said the administration has no authority to regulate the prices of drug products.

Advertise with us

Congress also prohibits Medicare from negotiating drug prices with manufacturers. As a result, the Center for Economic and Policy Research determined that for every dollar spent on drugs per person in the United States, Canada spent 70 cents, Japan 57 cents, Netherlands 50 cents, the United Kingdom 39 cents and Denmark only 35 cents, all of which negotiate prices with drug companies. The Federal Trade Commission watches drug prices but says prices “are due to normal market forces and thus do not present an antitrust issue.”

David Templeton: dtempleton@post-gazette.com or 412-263-1578